Nikki Schultek, founder of the global medical research consortium Intracell Research Group, takes a close look at how the COVID-19 pandemic may prompt a…
Two first-of-their-kind studies presented at the Alzheimer’s Association International Conference show transgender and nonbinary adults are more likely show early possible signs of dementia….
In light of last week’s long-awaited FDA decision on experimental Alzheimer’s treatment aducanumab, a panel of clinical trials experts looks at why Alzheimer’s drug…
The FDA is expected to decide whether or not to approve Biogen and Eisai’s experimental Alzheimer’s drug, aducanumab, in less than a week. Geri…
As part of our BrainTalk series, Being Patient spoke with Dr. Stephen Salloway about the development of aducanumab and what the future holds for…
In conversation with Being Patient leading up to the 2021 NIH Alzheimer’s Research Summit, University of Michigan assistant professor of neurology Dr. Lisa McGinley…
Pharmaceutical companies are making plans to leverage the emerging technology of quantum computing in hopes of accelerating the search for the next Alzheimer’s treatment….